Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ASTRAZENECA PHARMA   MYLAN
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-23
MYLAN
Dec-18
ASTRAZENECA PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs3,6203,975-   
Low Rs2,4382,188-   
Sales per share (Unadj.) Rs401.21,829.1-  
Earnings per share (Unadj.) Rs39.749.7-  
Cash flow per share (Unadj.) Rs46.2392.1-  
Dividends per share (Unadj.) Rs16.000-  
Avg Dividend yield %0.50-  
Book value per share (Unadj.) Rs234.41,978.8-  
Shares outstanding (eoy) m25.00514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x7.51.7 448.1%   
Avg P/E ratio x76.362.0 122.9%  
P/CF ratio (eoy) x65.57.9 833.9%  
Price / Book Value ratio x12.91.6 829.5%  
Dividend payout %40.30-   
Avg Mkt Cap Rs m75,7181,585,442 4.8%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m2,5910-   
Avg. sales/employee Rs Th026,887.8-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0730.1-  
INCOME DATA
Net Sales Rs m10,030941,074 1.1%  
Other income Rs m2610-   
Total revenues Rs m10,291941,074 1.1%   
Gross profit Rs m1,249243,515 0.5%  
Depreciation Rs m163176,206 0.1%   
Interest Rs m645,262 0.0%   
Profit before tax Rs m1,34122,047 6.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m348-3,507 -9.9%   
Profit after tax Rs m99325,554 3.9%  
Gross profit margin %12.525.9 48.1%  
Effective tax rate %26.0-15.9 -163.2%   
Net profit margin %9.92.7 364.6%  
BALANCE SHEET DATA
Current assets Rs m9,359525,495 1.8%   
Current liabilities Rs m4,844383,144 1.3%   
Net working cap to sales %45.015.1 297.6%  
Current ratio x1.91.4 140.9%  
Inventory Days Days4984 59.2%  
Debtors Days Days3993 41.9%  
Net fixed assets Rs m2,061182,553 1.1%   
Share capital Rs m50501 10.0%   
"Free" reserves Rs m5,8110-   
Net worth Rs m5,8611,018,070 0.6%   
Long term debt Rs m01,098,825 0.0%   
Total assets Rs m11,4212,730,861 0.4%  
Interest coverage x213.91.5 14,381.0%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x0.90.3 254.8%   
Return on assets %8.72.6 337.4%  
Return on equity %16.92.5 674.9%  
Return on capital %23.03.2 722.9%  
Exports to sales %00-   
Imports to sales %37.40-   
Net fx Rs m-3,1350-   
CASH FLOW
From Operations Rs m583195,555 0.3%  
From Investments Rs m181-101,081 -0.2%  
From Financial Activity Rs m-245-91,101 0.3%  
Net Cashflow Rs m5191,620 32.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.51 Rs / USD

Compare ASTRAZENECA PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ASTRAZENECA PHARMA With: DESH RAKSHAK  AURO LAB.  VAISHALI PHARMA   ZYDUS LIFESCIENCES  SANOFI INDIA  



Today's Market

Sensex Today Trades Higher | Just Dial Soars 10% | VST Industries, Indus Towers, ICICI Lombard Surge 5% Sensex Today Trades Higher | Just Dial Soars 10% | VST Industries, Indus Towers, ICICI Lombard Surge 5%(10:30 am)

Asian share markets are mixed today after US shares extended their losing streak to the longest since January 2024.